コーパス検索結果 (１語後でソート)
通し番号をクリックするとPubMedの該当ページを表示します
1 MMP inhibitors was about 30% that of [(18)F]fluorodeoxyglucose.
2 led Pittsburgh compound B and (18)F-labelled fluorodeoxyglucose.
3 with positron emission tomography using [18F]fluorodeoxyglucose.
4 e imaged by direct positron imaging of (18)F-fluorodeoxyglucose ((18)F-FDG) and fluorescence microsco
5 response [PR]), which was assessed by (18)F-fluorodeoxyglucose ((18)F-FDG) PET at the end of the tre
8 [average carotid]) after 24 months and (18)F-fluorodeoxyglucose ((18)F-FDG) PET/CT assessment of arte
10 e recommendations for the optimal use of (18)fluorodeoxyglucose ((18)F-FDG) PET/CT in patients with m
11 on-weighted MRI with standard clinical (18)F-fluorodeoxyglucose ((18)F-FDG) PET/CT scans in children
13 nd cellular inflammation, reflected by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomogra
14 the cellular inflammatory response by (18)F-fluorodeoxyglucose ((18)F-FDG) positron emission tomogra
15 ally, MEDI-573 significantly decreased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake in IGF-driven tumo
16 y cells have avidity for fluorine 18-labeled fluorodeoxyglucose ((18)F-FDG), and thus positron emissi
19 ollowed in mice with coronary ligation by 18-fluorodeoxyglucose ((18)FDG) positron emission tomograph
20 es and imaged sequentially using fluorine-18 fluorodeoxyglucose ((18)FDG) uptake as a nonspecific mar
22 mportant characteristics of incidental (18)F-fluorodeoxyglucose ([18 F]FDG) positron emission tomogra
23 We used PET/CT imaging with [(18)F]-labeled fluorodeoxyglucose ([(18)F]-FDG) in monkeys after monkey
24 ed in a subset of monkeys (n=8) using [(18)F]fluorodeoxyglucose ([(18)F]FDG) with positron emission t
25 in a multiparametric profile based on [(18)F]Fluorodeoxyglucose ([(18)F]FDG)-PET and DW-MRI, which id
27 ake of 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) as markers of active plaque
28 sed by 18F-sodium fluoride (18F-NaF) and 18F-fluorodeoxyglucose (18F-FDG) uptake with the use of posi
30 y was designed to evaluate the role of (18)F-fluorodeoxyglucose (18FDG) positron emission tomography/
31 ognostic factor measured on pretreatment 18F-fluorodeoxyglucose (18FDG)-positron emission tomography
32 and computed tomographic imaging with (18)F-fluorodeoxyglucose, a glucose analog, but the underlying
33 ), with a trend towards lower (18)F-labelled fluorodeoxyglucose also found in the left language netwo
34 oxel-wise group comparison of (18)F-labelled fluorodeoxyglucose and (11)C-labelled Pittsburgh compoun
35 ric head magnetic resonance imaging, [(18)F]-fluorodeoxyglucose and [(11)C] Pittsburg compound B posi
37 ams of administered activity for fluorine 18 fluorodeoxyglucose and iodine 131 sodium iodide were gen
40 isease (age range: 50-90) were scanned using fluorodeoxyglucose and Pittsburgh compound B positron em
41 the current clinical imaging standard (18)F-fluorodeoxyglucose at detecting non-glucose-avid metasta
43 .7%) with adequate follow-up had fluorine 18 fluorodeoxyglucose-avid IMLN, with a median standardized
45 fidence interval [CI], 2.3-28.3; P = .0008), fluorodeoxyglucose-avid lesions on baseline positron emi
46 for staging and response assessment for [18F]fluorodeoxyglucose-avid lymphomas in clinical practice a
48 an dual-echo GRE imaging for nodules without fluorodeoxyglucose avidity (68% vs 22%, respectively; P
49 with positron emission tomography and [F-18]fluorodeoxyglucose before and after 6 weeks of treatment
50 f colon tumors and colonic uptake of [(18)F]-fluorodeoxyglucose by positron emission tomography in Hd
51 ht to assess whether (18)F-fluoride or (18)F-fluorodeoxyglucose can identify culprit and high-risk ca
52 ce analysis revealed distinct (18)F-labelled fluorodeoxyglucose correlation patterns that greatly ove
54 itron emission tomography study with [(18)F]-fluorodeoxyglucose during euglycemic hyperinsulinemia.
55 oroparietal glucose metabolism determined by fluorodeoxyglucose F 18 [FDG]-labeled positron emission
56 aphy and brain imaging were unchanged, and a fluorodeoxyglucose F 18 positron emission tomographic sc
57 test this hypothesis, we evaluated F-labeled fluorodeoxyglucose ([F]FDG) and N-labeled ammonia ([N]NH
59 }]2) PET/computed tomographic (CT) and (18)F-fluorodeoxyglucose ( FDG fluorine 18 fluorodeoxyglucose
63 nd SUVmax, respectively) with those of (18)F fluorodeoxyglucose (FDG) across a variety of organs.
64 ) and CT (hereafter, PET/CT) with 6.9 mCi of fluorodeoxyglucose (FDG) and magnetic resonance (MR) ima
66 ted tomography (PET/CT) imaging with [(18)F]-fluorodeoxyglucose (FDG) can monitor monkeypox disease p
68 ission tomography (PET) studies with [(18)F]-fluorodeoxyglucose (FDG) during sleep and anesthesia, th
69 omography and magnetic resonance using (18)F-fluorodeoxyglucose (FDG) for glucose uptake was performe
70 and its implications for fluorine 18 ((18)F) fluorodeoxyglucose (FDG) imaging of atherosclerosis.
71 C11 Pittsburgh compound B (amyloid), and F18 fluorodeoxyglucose (FDG) in 90 clinically normal elderly
72 e role of metabolic imaging with fluorine 18 fluorodeoxyglucose (FDG) in breast cancer is reviewed.
73 the percentage injected dose of fluorine 18 fluorodeoxyglucose (FDG) in tumor from small-animal posi
74 pecific insulin-mediated fluorine 18 ((18)F) fluorodeoxyglucose (FDG) influx rates, tissue depots, an
75 Positron emission tomography using (18)F-Fluorodeoxyglucose (FDG) is an emerging modality for dia
78 s system primary neoplasm underwent same-day fluorodeoxyglucose (FDG) PET/CT and FDG PET/MR imaging.
79 d underwent clinically indicated fluorine 18 fluorodeoxyglucose (FDG) PET/CT and, immediately thereaf
80 ent clinically warranted fluorine 18 ((18)F) fluorodeoxyglucose (FDG) PET/CT followed by PET/MR imagi
81 FPPRGD2 PET/computed tomography (CT), (18)F fluorodeoxyglucose (FDG) PET/CT, and brain magnetic reso
82 on between metabolic activity at fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
83 omputed tomography (CT), fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
84 abdomen, and pelvis; and fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
85 (11)C]Pittsburgh compound B (PIB) and [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (P
87 ic nodal status with use of four fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
88 tabolism, exemplified by fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
89 -DPA-713 SPECT (4.06 +/- 0.52) versus [(18)F]fluorodeoxyglucose (FDG) positron emission tomography (P
90 o assess whether dynamic fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
91 netic resonance (MR) imaging and fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
93 ssess the diagnostic accuracy of fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
94 abolism in Parkinson's disease (PD) with 18F-fluorodeoxyglucose (FDG) positron emission tomography (P
96 aracteristics of interim fluorine 18 ((18)F) fluorodeoxyglucose (FDG) positron emission tomography (P
97 econd deep-inspiration breath hold (DIBH) in fluorodeoxyglucose (FDG) positron emission tomography (P
98 ed patterns of hypometabolism on fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
99 rast of melanin in comparison to fluorine 18 fluorodeoxyglucose (FDG) positron emission tomography (P
100 sburgh compound B (PIB; amyloid) and [(18) F]fluorodeoxyglucose (FDG) positron emission tomography.
102 , (11)C-deuterium-L-deprenyl (DED) and (18)F-fluorodeoxyglucose (FDG) respectively in presymptomatic
103 ase, who were referred for PET, using [(18)F]fluorodeoxyglucose (FDG) to assess for inflammation and
104 mography (PET) scanning and the tracer (18)F-fluorodeoxyglucose (FDG) to document regional metabolic
105 y and behavioral imaging with muPET and [18F]fluorodeoxyglucose (FDG) to generate whole-brain metabol
106 in lymphoma lesions and to compare these to fluorodeoxyglucose (FDG) uptake and biologic markers of
107 d November 2008 were reviewed for documented fluorodeoxyglucose (FDG) uptake in brown fat (n = 298).
109 pe 2 diabetes mellitus on carotid wall (18)F-fluorodeoxyglucose (FDG) uptake in patients with documen
110 tumor glucose metabolism as defined by (18)F-fluorodeoxyglucose (FDG) uptake since both have been ass
111 underwent brain magnetic resonance (MR), (18)fluorodeoxyglucose (FDG), and Pittsburgh compound B posi
113 nce, the radiolabeled glucose analogue, [18F]fluorodeoxyglucose (FDG), is routinely used in positron
114 was determined in vitro by MTT assay, [(18)F]fluorodeoxyglucose (FDG)- and [(18)F]fluorothymidine (FL
115 etermine the clinical significance of [(18)F]fluorodeoxyglucose (FDG)-avid lesions in patients with l
116 nce of arterial inflammation in the aorta by fluorodeoxyglucose (FDG)-PET, and LDL-cholesterol concen
117 raphy (PET), neuronal dysfunction via (18) F-fluorodeoxyglucose (FDG)-PET, and neurodegeneration via
118 of having abdominal or thoracic fluorine 18 fluorodeoxyglucose (FDG)-positive lesions underwent clin
120 s, we investigated whether noninvasive (18)F-fluorodeoxyglucose (FDG)-positron emission tomography (P
125 sured with positron emission tomography with fluorodeoxyglucose (FDG-PET) is of primary importance in
126 sitron emission tomography scans with [(18)F]fluorodeoxyglucose (FDG-PET) were used to assess tumor m
127 rrelated with lung inflammation (lung [(18)F]fluorodeoxyglucose [FDG] avidity) measured by positron e
128 [(11)C]3-O-methylglucose [3-OMG], and [(18)F]fluorodeoxyglucose [FDG]) to quantify, respectively, ske
130 positron emission tomography studies with 18-fluorodeoxyglucose in mice overexpressing tPA in neurons
132 and positron emission tomography with ((18)F)fluorodeoxyglucose injection was used to measure brain g
135 ) C-Pittsburgh compound B (n = 306) and (18) fluorodeoxyglucose (n = 305) positron emission tomograph
136 oups showed syndrome-specific (18)F-labelled fluorodeoxyglucose patterns, with greater parieto-occipi
139 thods Between 2010 and 2013, 219 fluorine 18 fluorodeoxyglucose PET examinations were performed in 11
140 retrospective study, the pretreatment (18)F fluorodeoxyglucose PET images in 101 patients treated wi
141 biomarker of cerebral amyloidosis, and (18) fluorodeoxyglucose PET imaging and hippocampal volume as
142 s for controlling the quality of fluorine 18 fluorodeoxyglucose PET imaging conditions to ensure the
144 stic approaches include the use of [(1)(8)F]-fluorodeoxyglucose PET to identify potential biopsy site
145 tion, because blankets are commonly used for fluorodeoxyglucose PET to maintain a normal body tempera
146 HD mutation carriers were scanned with [18F]-fluorodeoxyglucose PET to measure cerebral metabolic act
147 amyloid positron emission tomography (PET), fluorodeoxyglucose PET, and magnetic resonance imaging.
148 ET, posterior cortical metabolism with (18)F-fluorodeoxyglucose PET, hippocampal volume (age and sex
149 s of the disease, such as volumetric MRI and fluorodeoxyglucose PET, might better serve in the measur
150 increased BAT activity as measured by (18)F-fluorodeoxyglucose PET-CT in every volunteer, whereas ep
153 ons were evaluated at (18)F- FDG fluorine 18 fluorodeoxyglucose PET/CT and (18)F- FPPRGD2 2-fluoropro
154 l malignancies underwent two FDG fluorine 18 fluorodeoxyglucose PET/CT examinations within 1 week.
155 DS AND We performed (18)F-fluoride and (18)F-fluorodeoxyglucose PET/CT in 26 patients after recent tr
157 s recommended in multicenter FDG fluorine 18 fluorodeoxyglucose PET/CT studies on the basis of a high
158 d (18)F-fluorodeoxyglucose ( FDG fluorine 18 fluorodeoxyglucose ) PET/CT examinations were performed
161 ogical, magnetic resonance imaging and (18)F-fluorodeoxyglucose positon emission tomography data were
162 zole positron emission tomographic and (18)F-fluorodeoxyglucose positron emission tomographic imaging
163 gle-photon emission computed tomography, and fluorodeoxyglucose positron emission tomographic scans r
164 igh risk for atherosclerosis underwent (18)F-fluorodeoxyglucose positron emission tomographic/compute
166 ting brain metabolism measurement using (18) fluorodeoxyglucose positron emission tomography (31 pati
167 and explored the predictive value of [(18)F]fluorodeoxyglucose positron emission tomography ([(18)F]
168 on can be measured using fluorine-18-labeled fluorodeoxyglucose positron emission tomography ([(18)F]
170 zed by progressive hypometabolism on [(18)F]-fluorodeoxyglucose positron emission tomography (FDG-PET
171 application of functional imaging with (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET
172 eriodontal inflammation as assessed by (18)F-fluorodeoxyglucose positron emission tomography (FDG-PET
173 ables, atrophy on MRI, hypometabolism on 18F-fluorodeoxyglucose positron emission tomography (FDG-PET
175 hildhood temperament and high-resolution (18)fluorodeoxyglucose positron emission tomography (FDG-PET
176 group clinical trial that used early interim fluorodeoxyglucose positron emission tomography (FDG-PET
177 dy had undergone magnetic resonance imaging, fluorodeoxyglucose positron emission tomography (FDG-PET
178 ponse to treatment was evaluated using [18F] fluorodeoxyglucose positron emission tomography (PET) an
182 Structural magnetic resonance imaging, (18)F-fluorodeoxyglucose positron emission tomography (PET), a
183 rd improved outcomes at 1 year using an F-18-fluorodeoxyglucose positron emission tomography (PET)-as
184 ification software application to hybrid 18F-fluorodeoxyglucose positron emission tomography (PET)/co
185 oth computed tomography (CT) and fluorine-18 fluorodeoxyglucose positron emission tomography (PET)/CT
186 of regional brain metabolism (resting state fluorodeoxyglucose positron emission tomography [FDG-PET
187 terns of hypometabolism (measured by [(18)F] fluorodeoxyglucose positron emission tomography [FDG-PET
188 on emission tomography tracer uptake ([(18)F]fluorodeoxyglucose positron emission tomography [FDG-PET
189 intensity/contrast enhancement, and/or [18F]-fluorodeoxyglucose positron emission tomography [PET] up
190 ure cortical thickness alone; (iii) abnormal fluorodeoxyglucose positron emission tomography alone; (
191 med the veracity of this claim using (1)(8)F-fluorodeoxyglucose positron emission tomography and anat
192 y assess the diagnostic accuracy of Fluor-18-fluorodeoxyglucose positron emission tomography and comp
193 unctional consequences of cue exposure using fluorodeoxyglucose positron emission tomography and to r
194 e (BAL) was performed at 9 hours, and [(18)F]fluorodeoxyglucose positron emission tomography at 24 ho
195 imaging, diffusion tensor imaging and (18)F-fluorodeoxyglucose positron emission tomography at both
196 of Health (NIH) participants underwent 18-F Fluorodeoxyglucose Positron Emission Tomography Computed
198 ase signature cortical thickness or abnormal fluorodeoxyglucose positron emission tomography definiti
199 An additional 20 participants underwent fluorodeoxyglucose positron emission tomography followin
200 underwent metabolic brain imaging with (18)F-fluorodeoxyglucose positron emission tomography for atyp
201 eration (magnetic resonance imaging atrophy, fluorodeoxyglucose positron emission tomography hypometa
202 ative impact of stress-rest rubidium-82/F-18 fluorodeoxyglucose positron emission tomography identifi
204 lation with inflammation-induced fatigue and fluorodeoxyglucose positron emission tomography imaging,
206 (cross-sectionally); and hippocampal volume, fluorodeoxyglucose positron emission tomography results
207 e gold standard for diagnosis of RS; a (18)F-fluorodeoxyglucose positron emission tomography scan can
210 11195, (11)C-Pittsburgh compound B and (18)F-fluorodeoxyglucose positron emission tomography scans fo
211 lysis of cross-sectional resting-state (18)F-fluorodeoxyglucose positron emission tomography scans fr
212 tatistical parametric mapping of the [(18)F]-fluorodeoxyglucose positron emission tomography scans re
214 -positron emission tomography perfusion, and fluorodeoxyglucose positron emission tomography viabilit
219 necrosis factor-alpha therapy by using (18)F-fluorodeoxyglucose positron emission tomography with com
220 primate and functional neuroimaging ([(18)F]fluorodeoxyglucose positron emission tomography) with a
221 t standardized clinical assessment, brain 18-fluorodeoxyglucose positron emission tomography, electro
222 , or routine follow-up with biannual [(18)F]-fluorodeoxyglucose positron emission tomography-computed
223 patients and healthy controls underwent (18)fluorodeoxyglucose positron emission tomography-computed
224 disease burden obtained from baseline (18)F-fluorodeoxyglucose positron emission tomography-computed
225 isease (COPD) and may be quantified using 18-fluorodeoxyglucose positron emission tomography-computed
231 ng relied on the use of clinical fluorine 18 fluorodeoxyglucose positron emission tomography/computed
232 asive multimodality imaging) study underwent fluorodeoxyglucose positron emission tomography/computed
233 ely determine the prognostic value of [(18)F]fluorodeoxyglucose positron emission tomography/computed
234 report two cases of SOS investigated by 18F-fluorodeoxyglucose positron emission tomography/computed
235 study sought to determine the value of (18)F-fluorodeoxyglucose positron emission tomography/computed
236 We included individuals who underwent (18)F-fluorodeoxyglucose positron emission tomography/computed
237 glucose uptake in BAT, as assessed by [(18)F]fluorodeoxyglucose positron emission tomography/computed
238 rmal adjusted hippocampal volume or abnormal fluorodeoxyglucose positron emission tomography; and (v)
241 limits ventricular remodeling as assessed by fluorodeoxyglucose-positron emission tomographic imaging
242 ean cortical florbetapir uptake, mean (18) F-fluorodeoxyglucose-positron emission tomography (FDG-PET
246 lesions confirmed the same disease, and [18F]fluorodeoxyglucose-positron emission tomography demonstr
247 s 48 hours posttreatment (P < 0.05), whereas fluorodeoxyglucose-positron emission tomography did not
248 lso highly active in vivo as demonstrated by fluorodeoxyglucose-positron emission tomography imaging
250 taiodobenzylguanidine (MIBG) scans or [(18)F]fluorodeoxyglucose-positron emission tomography scans if
252 trasounds, computed tomography scans, [(18)F]fluorodeoxyglucose-positron emission tomography scans, m
253 tologic, vascular endothelial growth factor, fluorodeoxyglucose-positron emission tomography, and cli
257 ue inflammation than low-dose statins, using fluorodeoxyglucose-positron emission tomography/computed
258 ntation and reporting of surveillance [(18)F]fluorodeoxyglucose-positron emission tomography/computed
259 with severe carotid stenosis underwent (18)F-fluorodeoxyglucose-positron emission tomography/computed
260 lume (TMTV) measured at baseline with [(18)F]fluorodeoxyglucose/positron emission tomography-computed
264 used positron emission tomography and (18)F-fluorodeoxyglucose to measure brain glucose metabolism (
265 itron emission tomography was conducted with fluorodeoxyglucose to measure cerebral metabolism and Pi
266 anned with [(15)O]-labeled water and [(18)F]-fluorodeoxyglucose, to map regional cerebral blood flow
267 index, metabolic syndrome, and aortic (18)F-fluorodeoxyglucose uptake (a measure of arterial inflamm
269 on was most apparent in tumors with high (18)fluorodeoxyglucose uptake and aggressive oncological beh
270 sterol-modified agomiR-199a inhibits [(18)F]-fluorodeoxyglucose uptake and attenuates tumor growth in
272 t controlling for SVD, subtle differences in fluorodeoxyglucose uptake between early-onset AD and lat
275 that RA patients have increased aortic (18)F-fluorodeoxyglucose uptake in comparison with patients wh
279 omography (PET) -CT scan demonstrated [(18)F]fluorodeoxyglucose uptake in the right upper lobe mass a
280 atment (43 h) led to a 40% decrease in (18)F-fluorodeoxyglucose uptake in tumors relative to carrier
281 mediastinal adenopathy with increased [(18)F]fluorodeoxyglucose uptake on PET and scattered diffuse 1
282 gadolinium enhancement on MRI, increased (18)fluorodeoxyglucose uptake on positron emission tomograph
283 ding aorta at baseline and week 15, by (18)F-fluorodeoxyglucose uptake on positron emission tomograph
284 including magnetic resonance imaging, (18)F-fluorodeoxyglucose uptake positron emission tomography/c
285 ng our analysis to regions with high [(18)F]-fluorodeoxyglucose uptake provided the best combination
289 21 of 23 (91%) patients, whereas abnormal 18-fluorodeoxyglucose uptake was found in 15 of 23 (65%) ca
291 ection, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximum standardiz
292 inutes, compared with (18)F- FDG fluorine 18 fluorodeoxyglucose uptake with SUVmax maximum standardiz
293 ection of rapid inhibitory effects on [(18)F]fluorodeoxyglucose uptake, assessed through noninvasive
298 led Pittsburgh compound B and (18)F-labelled fluorodeoxyglucose values from functional network templa
300 Positron emission tomography and [(18)F]-fluorodeoxyglucose were employed to assess cerebral meta
WebLSDに未収録の専門用語（用法）は "新規対訳" から投稿できます。